



Frequently Asked Questions

What is the GO₂ Foundation for Lung Cancer?

Two of the most effective and influential nonprofit organizations serving the lung cancer community, the Bonnie J. Addario Lung Cancer Foundation (ALCF) and Lung Cancer Alliance (LCA) have proudly joined forces as **GO₂ Foundation for Lung Cancer**.

Together we become the “go-to” local and global force serving and advocating for the needs of the entire lung cancer community: those at risk, diagnosed, vulnerable and all others impacted or impacting the disease.

Why are ALCF and LCA joining forces?

GO₂ Foundation merges over three decades of combined expertise, shared philosophy and complementary programming to: maximize resources and staff expertise; integrate and grow collective networks to reach and support more people; expand patient-centered research and amplify awareness of the steep challenges and needs facing the lung cancer community.

With this fusion of talent, resources, influence and compassion, **GO₂ Foundation** is better positioned to transform what it means to live with lung cancer and to increase the patient survival rate of the world’s number one cancer killer annually.

What are the financial benefits of the organizations coming together?

The **GO₂ Foundation for Lung Cancer** combines the strengths and financial health of two organizations to become a national organization with locations in Washington, DC and the San Francisco Bay area that will help improve the lives of millions of those touched by lung cancer.

To help launch **GO₂ Foundation's** catalytic programs, a \$15 million challenge grant is being provided in memory of Skip Viragh, a respected and successful financial entrepreneur who inspired those around him to seek innovative solutions and high impact results. This grant, the largest single gift ever for lung cancer, will support **GO₂ Foundation's** vital work to unite a community that empowers people, increases survival, drives innovative research, and changes the future of lung cancer.

How will the merger improve on the services provided by the two organizations?

The effective and influential organizations coming together to form the **GO₂ Foundation for Lung Cancer** bring a shared “patients-first” philosophy as well as more than 30 years of combined experience that allow **GO₂** to offer comprehensive services to the lung cancer community including:

- Serving the at risk, patient and caregiver communities through professional, credible, free patient-support services that include personalized screening, treatment and clinical trial navigation, molecular testing, peer-to-peer mentoring, and support forums;

- Advancing world class academic, community and patient-centered research that spans the continuum of care for lung cancer detection, treatment and survivorship;
- Empowering millions to take direct advocacy action for a health care system that puts the interests of people first, to achieve historic increases in federal research funding, new treatment approvals and coverage and reimbursement for better access and delivery of care.
- Expanding access to excellence in screening, care, treatment and survivorship across all 50 states to ensure that anyone at risk or diagnosed with lung cancer benefits from life-saving services closer to home.

Who will lead the GO₂ Foundation for Lung Cancer?

Bonnie J. Addario, lung cancer survivor, will serve as co-founder and chair of the board of directors of **GO₂ Foundation**. She was most recently the founder and chair of ALCF. Laurie Fenton Ambrose will serve as co-founder, president and CEO of **GO₂ Foundation**. She was most recently the president and CEO of LCA.

How will the merger affect the services and programs we access? Will my contact for an existing project, program or event change?

Our goal is for the fusion of these two organizations into the **GO₂ Foundation for Lung Cancer** to be seamless. Your contact(s) will remain the same for any project, program or event unless otherwise noted.

Where will the GO₂ Foundation be headquartered?

The **GO₂ Foundation for Lung Cancer**, a 501(c)(3) non-profit, will have locations in the San Francisco Bay Area and Washington, DC, giving the organization a stronger reach across the nation.

What is the relationship between GO₂ Foundation for Lung Cancer and the Addario Lung Cancer Medical Institute (ALCMI)?

Founded in 2008, ALCMI is a separate and independent 501(c)(3) non-profit organization serving as a premier international patient-centric research consortium making innovative lung cancer studies possible through a unique collaboration of more than 25 world-class academic institutions and community investigators supported by centralized tissue banks and data systems. ALCMI is a vital collaborative partner with the **GO₂ Foundation** and recipient of multi-year grant funding to conduct priority research studies to advance **GO₂'s** mission. **GO₂ Foundation** and ALCMI staff will continue to communicate and collaborate on established and future patient-focused research projects when appropriate.